Sanofi GCVRZ 深 滬
已收盤 03-26 16:00:00 美东时间
0.8711
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.8711
- 總市值 1113.52亿
- 52周最高 0.882
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.43
- 委 比 0.00%
- 總股本 1278.30亿
- 歷史最高 0.882
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.153
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sanofi gains EU approval recommendation for Scarlisa subcutaneous version
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding approval of a subcutaneous formulation of Sanofi's (SNY) Scarlisa (isatuximab) a...
03-27 22:56
AstraZeneca Strengthens Position In COPD Race With Successful Trials
AstraZeneca reports Phase 3 success for tozorakimab in COPD, reducing exacerbations and showing strong safety across broad patient groups.
03-27 20:46
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval
BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval March 27 (Reuters) - Sanofi SA SASY.PA : SANOFI’S SARCLISA SUBCUTANEOUS FORMULATION ADMINISTERED VIA ON-BODY INJECTOR RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT MULTIPLE MYELOMA IF APPROVED, SARCL
03-27 20:03
UPDATE 3-AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials
UPDATE 3-AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials Rival treatments had mixed results in the past AstraZeneca sees $3-5 billion peak annual sales for its drug Detailed results to be presented at upcoming medical conference Shares among biggest gainers on FTSE 10
03-27 16:03
Geron Announces Appointment of New Members to its Board of Directors
Geron Corporation announced the appointment of Patricia S. Andrews and Constantine Chinoporos to its Board of Directors. Both bring extensive experience in the biopharmaceutical industry, particularly in commercial-stage organizations. Their expertise will support Geron's strategic priorities and the commercial growth of RYTELO<sup>®</sup>, a treatment for lower-risk myelodysplastic syndromes/neoplasms (LR-MDS). Andrews and Chinoporos have held s...
03-26 12:00
赛诺菲(SNY)股票3月25日盘中上涨3.33%：背后推手曝光
• FDA 授予 venglustat 治疗戈谢病的突破性疗法认定。 • 日本批准 Dupixent 用于治疗成人大疱性类天疱疮。 • 赛诺菲获得自身免疫性疾病抗体 KT501 的全球权益。
03-25 19:17
Japan MHLW approves Dupixent for moderate-to-severe bullous pemphigoid adults
Japan MHLW approves Dupixent for moderate-to-severe bullous pemphigoid adults Japan’s health ministry approved Dupixent (dupilumab) to treat adults with moderate-to-severe bullous pemphigoid, according to Regeneron and Sanofi. In the LIBERTY-BP-ADEPT Phase 2/3 trial, sustained disease remission at W
03-24 14:01
Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.
03-24 01:59
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment March 23 (Reuters) - Kali Therapeutics said on Monday it has entered into a licensing agreement with French drugmaker Sanofi SASY.PA to develop the privately held firm's experimental treatment for several autoimmune diseases. H
03-23 19:51
Trump administration reportedly shortlisting CDC nominees
Two physicians with somewhat contrasting views on vaccines are among the potential candidates the Trump administration is considering as its pick to lead the U.S. Centers for Disease Control and Preve...
03-22 00:24
